The Side Hustle Nobody Expected

A team of researchers led by Yun Wang and colleagues just discovered that FLT3-ITD has been running a secret operation completely separate from its day job as a kinase. Published in Blood, their study reveals that this mutant protein moonlights as a scaffold - essentially a molecular meeting room where two other troublemakers, PKCι and STAT1, can get together and scheme.

Think of it like this: if regular FLT3 is an overeager manager constantly sending emails (kinase activity), FLT3-ITD is simultaneously hosting unsanctioned meetings in the conference room (scaffold activity). And these meetings have consequences.

When Proteins Conspire

The researchers found that FLT3-ITD physically brings together PKCι (an enzyme implicated in multiple cancers) and STAT1 (a transcription factor that controls which genes get turned on). When these three proteins form their little club, PKCι phosphorylates STAT1 at a very specific spot - serine 727 (S727).

Here's where it gets interesting. STAT1 normally requires phosphorylation at tyrosine 701 (Y701) to do its usual job. But this S727 phosphorylation? It's a completely different activation mode - a noncanonical pathway that bypasses the normal rules.

The result of this unauthorized phosphorylation: STAT1 cranks up production of CD276 (also known as B7-H3), an immune checkpoint protein that's notoriously good at helping tumors hide from the immune system.

Your T Cells Are Getting Very Sleepy

CD8+ T cells are supposed to be your body's elite tumor-hunting squad. But when they encounter CD276-coated leukemia cells, they basically fall asleep on the job - a phenomenon scientists call T cell exhaustion.

The Wang study analyzed 104 patient samples and found exactly this pattern: patients with FLT3-ITD mutations had profound CD8+ T cell exhaustion. These tired immune cells showed reduced killing ability, couldn't proliferate properly, stopped producing the inflammatory signal IFN-γ, and started expressing inhibitory markers - like security guards who've given up and are now helping the robbers carry boxes.

The Comeback Tour

The researchers didn't stop at diagnosis. They tested whether blocking CD276 could wake up those exhausted T cells. The results were impressive: targeting CD276 restored T cell function by 1.2-1.7 fold for cytotoxicity, 1.4-1.7 fold for proliferation, and 1.5-1.8 fold for IFN-γ production.

Even better, when they combined the FLT3 inhibitor quizartinib with CD276-targeting agents in mouse models, tumor burden dropped by 72.9%-80.4% - significantly outperforming quizartinib alone.

What This Means for Patients

This research fundamentally changes how we think about FLT3-ITD mutations. It's not just about blocking an overactive enzyme anymore. These leukemia cells have developed an entirely separate strategy for evading the immune system - one that current FLT3 inhibitors don't fully address.

The implication is tantalizing: combining FLT3 inhibitors with immunotherapy targeting CD276 might finally crack the code on this aggressive leukemia subtype. CD276-targeting drugs are already in clinical trials for various cancers, which means this combination approach could reach patients relatively quickly.

For the roughly one in four AML patients whose leukemia carries an FLT3-ITD mutation, that meeting in the molecular conference room might finally be getting shut down.

References:

1. Wang Y, Chen S, Liu S, et al. FLT3-ITD scaffolds PKCι-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML. Blood. 2025. DOI: 10.1182/blood.2025032254

2. Swords RT, Coutre S, Maris MB, et al. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. Expert Opin Investig Drugs. 2024. PMID: 39538314

3. Soverini S, et al. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res. 2007. PMID: 17570678

4. Seo H, et al. B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades. Front Immunol. 2025. PMCID: PMC12420428

5. Wherry EJ. T cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015. DOI: 10.1038/cddis.2015.162

6. Ronai Z, et al. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine. 2017. PMCID: PMC5832629

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.